FDA Granted Breakthrough Status to CIMZIA for APS

The designation aims to accelerate the development of a treatment for pregnancy complications in patients with APS.

Updated on Sept. 22, 2026 in Pregnancy

Bold flat-color editorial illustration featuring a glass medical vial and geometric molecules, representing pharmaceutical regulatory progress in a clinical context. — The FDA granted Breakthrough Therapy designation to Cimzia, marking a significant step toward the first approved treatment for pregnancy complications in patients with antiphospholipid syndrome. AI Illustration. Upload story photo >

Live Poll

Should federal regulators prioritize faster development paths for new treatments for rare medical conditions?

The FDA has granted Breakthrough Therapy designation to CIMZIA to help prevent adverse pregnancy outcomes in women with antiphospholipid syndrome (APS). The medication works by inhibiting tumour necrosis factor activity in patients with this autoimmune disorder.

Why it matters

Currently, there are no FDA-approved therapies specifically designed to prevent pregnancy complications for women with APS. This new designation is intended to expedite the clinical review process for this serious condition.

CIMZIA is a tumour necrosis factor inhibitor that is administered via injection. UCB also maintains an Orphan Drug designation for the therapy, though its formal efficacy in preventing placenta-mediated pregnancy outcomes remains unproven.

The players

FDA

The United States Food and Drug Administration is the federal agency responsible for regulating pharmaceuticals and ensuring the safety of medical products.

UCB

UCB is a global biopharmaceutical company that develops medications for severe diseases in immunology and neurology.

The details

APS is an autoimmune disorder often associated with dangerous blood clots and complications during pregnancy. The therapy aims to reduce inflammation by blocking tumour necrosis factor activity in the body.

September 22, 2026: The designation was officially announced.

Culture Shift

This development marks a shift toward specialized prenatal care for patients with autoimmune conditions. It follows the precedent of the IMPACT study, which provided the preliminary evidence needed to secure this regulatory milestone.

The designation does not yet change the availability of the drug for patients, as its safety and efficacy for this purpose remain under investigation. Patients should continue to consult their obstetricians regarding existing management routines for APS.

The takeaway

Breakthrough Therapy designations are designed to speed up the development of life-saving medical treatments for serious conditions. Patients should maintain open communication with their healthcare providers to track the progress of ongoing clinical trials.